Diabetes

Top Story

New combination insulin, GLP1 receptor agonists in development

September 24, 2016

The French biotechnology company Adocia announced the launch of a program to develop two new drugs combining insulin and GLP-1 receptor agonists to treat type 2 diabetes, according a company press release.

The combinations — insulin glargine (Lantus, Sanofi) plus dulaglutide (Trulicity, Eli Lilly) and insulin glargine plus liraglutide (Vicotza, Novo Nordisk) — will use Adocia’s BioChaperone technology, which solubilizes and stabilizes insulin glargine in an aqueous solution. This allows it to combine with the two GLP-1 receptor agonists.

In the Journals Plus

Diet quality affects type 2 diabetes risk

September 21, 2016
Adults without diabetes who improve the quality of their diet are at lower risk for developing type 2 diabetes than those whose diet quality deteriorates, according to…
FDA News

FDA approves fixed-dose combination canagliflozin, metformin extended release

September 21, 2016
The FDA has approved a once-daily, fixed-dose combination therapy of the SGLT2 inhibitor canagliflozin and extended-release metformin for first-line use to treat type 2…
In the Journals

Less than 10% of diabetes initiatives include hypoglycemia performance measure

September 20, 2016
Despite a universal inclusion of hypoglycemia in diabetes clinical practice guidelines, the condition is rarely included as a performance measure of patient care…
CME Video

Secondary Prevention of Atherothrombotic Events: Current Insights on Advancing Science

This activity is supported by an educational grant from Merck & Co.

Prevention of cardiovascular disease (CVD) is critical in light of its associated mortality, morbidity, and economic…
More »
Video
Meeting News Coverage

VIDEO: Creative moonlighting can offer diabetes educators opportunities to supplement income

August 30, 2016
More »
Featured
CME

Diabetic Retinopathy: The Importance of Early Screening, Referral, and Management

This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Diabetic eye disease is one of the most common causes of vision loss in the United States. As the rates of diabetes…
More »

New combination insulin, GLP1 receptor agonists in development

September 24, 2016
The French biotechnology company Adocia announced the launch of a program to develop two new drugs combining insulin and GLP-1 receptor agonists to…

In the Journals Plus

Diet quality affects type 2 diabetes risk

September 21, 2016
Adults without diabetes who improve the quality of their diet are at lower risk for developing type 2 diabetes than those whose diet quality…

FDA News

FDA approves fixed-dose combination canagliflozin, metformin extended release

September 21, 2016
The FDA has approved a once-daily, fixed-dose combination therapy of the SGLT2 inhibitor canagliflozin and extended-release metformin for first-line…

In the Journals

Less than 10% of diabetes initiatives include hypoglycemia performance measure

September 20, 2016
Despite a universal inclusion of hypoglycemia in diabetes clinical practice guidelines, the condition is rarely included as a performance measure of…

Meeting News Coverage

HbA1c lowering models predict reductions in microvascular, macrovascular complications

September 19, 2016
In adults with type 2 diabetes and known cardiovascular disease, each 1% decrease in HbA1c is associated with a relative risk reduction in…

Meeting News Coverage

Marriage halves risk for overweight in adults with type 2 diabetes

September 19, 2016
Adults with type 2 diabetes who are married and living with their spouse are 50% less likely to develop overweight vs. single adults with diabetes…

Meeting News Coverage

Exenatide, dapagliflozin combination improves glycemic control

September 19, 2016
A combination of the glucagon-like peptide-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin is more effective for improving…

Diabetes in Real Life

Educators can raise awareness of sexual complications in diabetes

Endocrine Today, September 2016
In this issue, Susan Weiner, MS, RDN, CDE, CDN, talks with diabetes educators Janis Roszler, MS, RD, LD/N, CDE, FAND, and Donna Rice, MBA, BSN, RN

Follow-up often poor after gestational diabetes

Endocrine Today, September 2016
Competing priorities and a low motivation for self-care often prevent women with gestational diabetes from undergoing continued postpartum monitoring…

Meeting News Coverage

Anabolic steroid use associated with impaired insulin sensitivity in men

September 19, 2016
Men who abuse or have abused anabolic androgenic steroids have lower insulin sensitivity and more visceral fat than controls, possibly mediated by…

More Headlines »
morganatic-roan
morganatic-roan